Why Some Are Observed

Premature atrial complexes (PACs) and premature ventricular complexes (PVCs) are present in nearly every human heart. The mechanism is typically a small focus of automaticity or triggered activity in otherwise healthy tissue. The focus fires, produces a single early beat, and then sinus rhythm resumes.

In a structurally normal heart, isolated PVCs carry no risk of sudden death. The healthy tissue surrounding the focus cannot sustain reentry — there's no scar, no slow conduction zone, no substrate for a lethal spiral. The PVC fires, the ventricle contracts once, and the next sinus beat resets the cycle.

The threshold for concern is burden. When PVCs exceed roughly 15-20% of all heartbeats over 24 hours, the constant asynchronous contraction can, over months to years, weaken the ventricle — a phenomenon called PVC-induced cardiomyopathy. Below that burden, in a normal heart, observation and reassurance are appropriate.

Atrial fibrillation is the most common arrhythmia where "observation" (in the form of rate control) is a legitimate long-term strategy. The reasoning is mechanistic.

In longstanding persistent AFib, the atrial tissue has remodeled extensively. Fibrosis is widespread, the atrial myocytes have shortened their refractory periods, and the substrate for chaotic wavelet propagation is self-sustaining. Restoring sinus rhythm is possible (cardioversion, drugs, ablation), but the atria are primed to fibrillate again because the substrate hasn't changed.

In this setting, the clinical question shifts. The primary harm of AFib isn't the irregular rhythm itself — it's the ventricular rate and the stroke risk. If you control the rate (keeping the ventricle from beating too fast) and anticoagulate (preventing clot formation in the stagnant left atrial appendage), the patient's major risks are addressed without attacking the atrial rhythm directly.

Rate control is observation with guardrails. You accept that the atria will fibrillate and focus on protecting the patient from the consequences. The mechanism of harm (rapid ventricular response, thromboembolism) is managed even though the mechanism of the arrhythmia (chaotic reentry) is left alone.

Rhythm control becomes more appealing in paroxysmal or early persistent AFib — when the substrate is still reversible, when sinus rhythm can be maintained, when the patient is highly symptomatic, or when rate control fails to relieve symptoms. The EAST-AFNET 4 trial demonstrated that early rhythm control (within a year of diagnosis) reduces cardiovascular events, likely because maintaining sinus rhythm prevents the progressive atrial remodeling that makes AFib permanent.

Every therapy carries risk. Ablation near the His bundle can cause permanent complete heart block. Antiarrhythmic drugs have proarrhythmic potential — the very agents designed to suppress arrhythmias can, in the wrong substrate, create new ones (as we explored in Volume VII).

A patient with rare, brief runs of non-sustained VT on a structurally normal heart faces a concrete decision. The NSVT itself is hemodynamically trivial and carries no mortality risk. Ablation would require mapping the focus, which may be deep in the septum or near the conduction system. The procedural risk — even if small — exists for a rhythm that poses essentially no danger.

Similarly, an asymptomatic patient with an incidentally discovered accessory pathway (WPW pattern on ECG, never symptomatic) presents a nuanced scenario. The pathway carries a small risk of rapid conduction during AFib, but the annual event rate is low. Ablation is curative and relatively safe, but the decision depends on the patient's risk tolerance, the pathway's conduction properties, and whether the pathway location makes ablation straightforward or risky.

In all these cases, understanding the mechanism tells you what could happen. Clinical judgment tells you what's likely to happen and whether intervention changes that likelihood enough to justify the risk.